Drugs / Carbogen
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01123005 | Dec 2010 → Aug 2015 | neoplasm | Stanford University | Terminated | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT01370044 | Aug 2012 → Jun 2015 | — | Charite University, Berlin, Germany | Terminated | Missed primary |
| Phase 33 trials | ||||||
| Phase 3 | NCT06770426 | Feb 2025 → Sep 2027 expected | ischemic stroke | Yonsei University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04839224 | Apr 2021 → Oct 2022 | ischemic stroke | Yonsei University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00033436 | Oct 2000 → Nov 2008 | urinary bladder cancer | Mount Vernon Cancer Centre at Mount Vernon Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Carbogen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04839224 ↗ |
| Known as | Carbon Dioxide | “Carbon Dioxide (Carbogen) for the Treatment of Febrile Seizures” NCT01370044 ↗ |
| Modality | Other / unclassified | “Carbogen is a mixture of 5% CO2 with 95% O2.” NCT04839224 ↗ |
| Route | Inhaled | “carbogen through a closed breathing system (face mask with a tight air seal or a mouthpiece with nasal clip)” NCT00033436 ↗ |